AbbVie Inc. (ABBV): Price and Financial Metrics
AbbVie Inc. (ABBV)
Today's Latest Price: $72.67 USD
Updated Mar 27 12:00am
Add ABBV to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ABBV Stock Summary
- ABBV has a higher market value than 98.66% of US stocks; more precisely, its current market capitalization is $99,805,636,646.
- The capital turnover (annual revenue relative to shareholder's equity) for ABBV is -4.07 -- better than just 3.06% of US stocks.
- ABBV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 2.11% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to AbbVie Inc are TXN, BMY, AMGN, GILD, and AZN.
- Visit ABBV's SEC page to see the company's official filings. To visit the company's web site, go to www.abbvie.com.
ABBV Stock Price Chart More Charts
ABBV Price/Volume Stats
| Current price | $72.67 | 52-week high | $97.86 |
| Prev. close | $73.83 | 52-week low | $62.55 |
| Day low | $70.71 | Volume | 12,293,200 |
| Day high | $75.06 | Avg. volume | 12,216,435 |
| 50-day MA | $84.76 | Dividend yield | 6.5% |
| 200-day MA | $78.67 | Market Cap | 107.31B |
AbbVie Inc. (ABBV) Company Bio
Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.
ABBV Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $72.67 | $209.97 | 184% |
We started the process of determining a valid price forecast for AbbVie Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that AbbVie Inc ranked in the 67th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 185.83% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of AbbVie Inc, consider:
- The company's balance sheet shows it gets 62% of its capital from equity, and 38% of its capital from debt. Its equity weight surpasses that of merely 20.94% of free cash flow generating stocks in the Healthcare sector.
- AbbVie Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 10.56% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 179% |
| 1% | 182% |
| 2% | 184% |
| 3% | 187% |
| 4% | 190% |
| 5% | 193% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ABBV, try NVO, SEM, JAZZ, AGN, and HCA.
Top Stories View All
Top 4 Home Improvement Stocks with Stimulus Checks on the Way
Rip Your Face Off Rally!
Best & Worst Performing Stock Industries for March 27, 2020
Best & Worst Performing Small Cap Stocks for March 27, 2020
Best & Worst Performing Mid Cap Stocks for March 27, 2020
View All Top Stories
Loading social stream, please wait...